Full-Time
Medical Writer
Multiple Teams
Posted on 9/30/2025
Inizio Engage
501-1,000 employees
Provides integrated data insights for pharma
No salary listed
London, UK + 1 more
More locations: Manchester, UK
Hybrid
This is a hybrid remote/in-office role.
 Content & Writing (1) |
|---|
- Must have a graduate degree (PharmD, MS, MD) in the life sciences, pharmacology, or medicine
- Fluency in conducting literature searches
- Working knowledge of the pharmaceutical industry in the drug development and commercialization processes
- Research material for assigned projects, including performing literature searches
- Leverage approved outlines and the support of the senior scientific team to write referenced drafts that are:
- + Medically and scientifically accurate
- + Clear, well-written, and engaging
- + In consideration of the scientific strategy
- + Appropriate to the audience
- + Appropriate to the deliverable type (print, digital, film and workshop)
- + In consideration of the supplied style guide or writing template
- Infuse instructional design elements (eg, learning goals, practice activities, assessment questions) into written materials with the support of the senior scientific and learning experience design teams
- Incorporate feedback (internal reviews, client feedback, MLR feedback)
- Mark up references to support your writing
- Incorporating copyedit and fact check changes
- Attend internal and external meetings and develop the skills needed to represent scientific, including answering content-related questions and presenting ideas
- Collaborate with internal team members from creative, learning experience design, performance, learning delivery, and editorial
- Manage time to ensure that projects are delivered within the budgeted hours
- Complete all work within the allocated time and following project specifications
- 1+ years of experience in pharmaceutical sales training is a bonus
Inizio Engage turns scattered data into integrated insights and learning solutions for the pharmaceutical and biotechnology sectors. Its PROPENSITY4 data platform combines data from multiple sources to support decision making across customer needs, commercial operations, and strategic goals. The ecosystem includes Ashfield Excellence Academy, Axiom, Cormis, and Logicearth, which provide training, communications, and capability-building programs for pharma commercial and medical teams. By pairing data analytics with targeted training and talent development, the company helps patients, healthcare professionals, and pharmaceutical firms improve outcomes and gain competitive advantages.
Company Size
501-1,000
Company Stage
N/A
Total Funding
N/A
Headquarters
Upper Dublin Township, Pennsylvania
Founded
N/A
Simplify's Take
What believers are saying
- Nazaré Access Academy addresses growing US patient access complexity for pharma.
- PROPENSITY4 transforms disparate data into integrated insights for commercial optimization.
- Strategic leadership appointments signal potential for streamlined operations and market expansion.
What critics are saying
- Nazaré brand consolidation cannibalizes legacy divisions' revenue within 6-12 months.
- IQVIA's integrated platforms directly compete with PROPENSITY4's data analytics services.
- AI-powered learning platforms displace human-led training, halving demand by 2028.
What makes Inizio Engage unique
- End-to-end commercialization partner spanning discovery through post-launch lifecycle.
- Integrated suite connecting medical affairs, data insights, and creative engagement capabilities.
- 5,000+ professionals across 20+ countries delivering localized pharmaceutical expertise globally.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Private Medical Insurance
Life Insurance
Pension Scheme
Hybrid Work Options
Paid Vacation
401(k) Retirement Plan
Company News
Inizio Engage CEO Jim Sage featured in pharmaphorum's "12 Questions" series. Discover Jim Sage's insights on leadership, industry challenges, and the transformative impact of data, technology, and patient-centric innovation in his latest pharmaphorum "12 Questions" interview. We're pleased to share that Jim Sage, Global CEO and President of Inizio Engage, has been featured in pharmaphorum's latest "12 Questions" interview series. In the conversation, Jim reflects on his career across international markets, his motivations as a leader, and the experiences that have shaped his approach to building high-performing teams. He also explores some of the most pressing challenges facing the pharmaceutical industry today, including pricing pressures, launch performance, and the need for new reimbursement models. Jim highlights how data, technology, and AI are already transforming the way organisations operate, and discusses the growing importance of patient-centric approaches, from HUB services to personalised support throughout the treatment journey. This content was provided by Inizio Discover Jim Sage's insights on leadership, industry challenges, and the transformative impact of data, technology, and patient-centric innovation in his latest pharmaphorum "12 Questions" interview. As the understanding of obesity continues to evolve, so too does the science, patient experience, and cross-sector collaboration driving innovation. At ObesityWeek(R) 2025 in Atlanta, experts from across Inizio reflected... Discover how our DataGateway platform unifies fragmented real-world oncology data into a single, validated dataset that delivers deeper insights and faster decision-making. Inizio today announced the launch of InConcert(TM), a new AI-powered data solution designed to accelerate smarter, evidence-led decisions during the critical pre-launch phase of the product lifecycle. Discover key insights from ESMO 2025 on how design, emotion, and sustainability are reshaping medical congress experiences. Featuring expert takes from Inizio leaders. As the global hematology community prepares for the 67th ASH(R) Annual Meeting and Exposition, Inizio experts share their perspectives on what's driving the field forward - and how pharma companies... At Inizio Medical, we believe AI isn't replacing Medical Affairs - it's redefining what's possible. Our platform, iON.AI(TM), enhances human expertise, streamlines complex workflows, and strengthens strategic impact through seamless... Discover how Inizio experts are shaping the future of obesity care - where science, strategy, and innovation unite to advance cardiometabolic health and drive real-world impact. At Fierce Pharma Week, Inizio revealed how the fusion of human expertise and purposeful AI is reshaping pharma communications and driving real-world impact - discover how this human-centered innovation is defining the... Inizio is leading the way in Intelligent Commercialization(TM) by uniting proprietary AI-powered platforms, deep scientific expertise, and proven governance to unlock measurable, lasting value at every stage of commercialization. * 1 * 2 * 3 * 4 * 5 * 6 * 7 * 8 * 9 * 10 * 11 * 12 * 13 * 14 * 15 * 16 * 17 * 18 * 19 * 20 * 21 * 22 * 23 * 24 * 25 * 26 * 27 * 28 * 29 * 30 * 31 * 32 * 33 * 34 * 35 * 36 * 37 * 38 * 39 * 40 * 41 * 42 * 43 * 44 * 45 * 46 * 47 * 48 * 49 * 50
We're proud to announce that our teams across Inizio Evoke, Inizio Engage, and Inizio Medical have been named finalists in six prestigious categories at the 2025 PM360 Trailblazer Awards, which recognize excellence and innovation in healthcare marketing.
Inizio, a global commercialisation partner to health and life sciences companies, has appointed Ryan Quigley as chief executive.
After a review of potential Patient Support Program (PSP) partners in Italy, Inizio Engage has formed a collaboration with Egg, head quartered in Milan.
Inizio announced that Remco op den Kelder has been appointed to the president of Inizio Advisory and Jim Sage will become president of Inizio Engage.